<DOC>
	<DOCNO>NCT01316523</DOCNO>
	<brief_summary>Lenalidomide show single agent activity indolent Non-Hodgkin 's Lymphoma . It approve treatment multiple myeloma myelodysplastic syndrome . Rituximab effective single agent combination chemotherapy indolent Non-Hodgkin 's Lymphoma . The purpose study see well give lenalidomide together rituximab work treat patient previously untreated indolent Non Hodgkin 's Lymphoma . Lenalidomide take 20 mg daily , day 1-21 28 day cycle , continue disease progress , unacceptable side effect twelve cycle patient respond well . Rituximab 375 mg/m2/wk x 4 week begin Day 15 cycle 1 . After 4 cycle therapy , patient respond well treatment , patient receive second course Rituximab . Blood sample collect assess immune system functioning .</brief_summary>
	<brief_title>Lenalidomide Rituximab Subjects With Previously Untreated Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . All patient must inform investigative nature clinical trial give write informed consent accordance institutional federal guideline . 2 . Age great equal 18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Previously untreated , histologically confirm indolent lymphoma include follicle cell lymphoma , WHO classification , grade I II , marginal zone lymphoma . Bone marrow biopsy sole mean diagnosis acceptable , may submit conjunction nodal biopsy . Fine needle aspirate acceptable . 5 . At least one measurable lesion accord International Working Group Response criterion lymphomas . There must measurable lymphadenopathy follow serial exam and/or image . 6 . Submission original biopsy review local staff hematopathologist . 7 . ECOG performance status 0 2 study entry . 8 . No major organ dysfunction laboratory test result within range : Absolute neutrophil count great equal 1000 /uL Platelet count great equal 75 x 109/L Total bilirubin less equal 2.0 mg/dL . HIV negative Subjects must calculate creatinine clearance ≥ 30ml/min CockcroftGault formula . See section , `` Dosing Regimen '' , regard lenalidomide dose adjustment calculate creatinine clearance ≥ 30ml/min &lt; 60ml/min . 9 . Life expectancy great 3 month . 10 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 10 14 day prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . 11 . Disease free prior malignancy great equal 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast 12 . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation . ( patient intolerant aspirin may use low molecular weight heparin ) . 13 . Must able swallow lenalidomide capsule . 1 . Any prior treatment NonHodgkin 's Lymphoma . 2 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 3 . Pregnant breastfeeding female . ( Lactating female must agree breast feed take lenalidomide ) . 4 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 5 . Use experimental drug therapy within 28 day baseline . 6 . Known hypersensitivity thalidomide rituximab . 7 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 8 . Any prior use lenalidomide . 9 . Concurrent use anticancer agent treatment . 10 . Known positive HIV 11 . Known active hepatitis , type A , B C. 12 . Evidence CNS metastatic disease 13 . Subjects ≥ Grade 2 neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Rituximab</keyword>
	<keyword>untreated indolent Non-Hodgkin 's Lymphoma</keyword>
</DOC>